GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012
- PDF / 456,984 Bytes
- 17 Pages / 595.276 x 790.866 pts Page_size
- 93 Downloads / 189 Views
EDUCATIONAL SERIES
–
RED SERIES
NEW TRENDS IN CLINICAL ONCOLOGY
GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012 A. Gonza´lez Martı´n • A. Redondo • M. Jurado • A. De Juan • I. Romero • I. Bover • J. M. Del Campo • A. Cervantes • Y. Garcı´a • J. A. Lo´pez-Guerrero C. Mendiola • J. Palacios • M. J. Rubio • A. Poveda Velasco
•
Received: 20 December 2012 / Accepted: 21 December 2012 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract In 2006, under the auspices of The Spanish Research Group for Ovarian Cancer (Spanish initials GEICO), the first ‘‘Treatment Guidelines in Ovarian Cancer’’ were developed and then published in Clinical and Translational Oncology by Poveda Velasco et al. (Clin Transl Oncol 9(5):308–316, 2007). Almost 6 years have elapsed and over this time, we have seen some important developments in the treatment of ovarian cancer. Significant changes were also introduced after the GCIG-sponsored 4th Consensus Conference on Ovarian Cancer by Stuart et al. (Int J Gynecol Cancer 21:750–755, 2011). So we decided to update the treatment guidelines in ovarian cancer and, with this objective, a group of investigators of
A. Gonza´lez Martı´n (&) Medical Oncology Department, MD Anderson Cancer Center, C/Arturo Soria, 270, 28033 Madrid, Spain e-mail: [email protected]
the GEICO group met in February 2012. This study summarizes the presentations, discussions and evidence that were reviewed during the meeting and during further discussions of the manuscript. Keywords Ovarian cancer Treatment guidelines Chemotherapy Surgery First line Recurrent disease
Methodology During one and a half-day meeting, several topics on the management of ovarian cancer (OC) were reviewed by a panel of experts from GEICO about different areas. Each J. M. Del Campo Department of Medical Oncology, Vall d’Hebron University Hospital, Barcelona, Spain
A. Redondo Medical Oncology Department, University Hospital La Paz, Madrid, Spain
A. Cervantes Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, Hospital Clı´nico Universitario, University of Valencia, Valencia, Spain
M. Jurado Department of Gynecology, School of Medicine, University of Navarra, Pamplona, Spain
Y. Garcı´a Department of Medical Oncology, Sabadell Hospital, Parc Taulı´ Healthcare Corporation, Sabadell, Barcelona, Spain
A. De Juan Department of Medical Oncology, University Hospital Marque´s de Valdecilla, Santander, Spain
J. A. Lo´pez-Guerrero Laboratory of Molecular Biology, Fundacio´n Instituto Valenciano de Oncologı´a, Valencia, Spain
I. Romero Department of Medical Oncology, Fundacio´n Instituto Valenciano de Oncologı´a, Valencia, Spain
C. Mendiola Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
I. Bover Medical Oncology Department, Hospital Son Lla`tzer, Palma de Mallorca, Islas Baleares, Spain
J. Palacios Department of Pathology, University Hospital Ramo´n y Cajal, Madrid, Spain
123
Cl
Data Loading...
